Eli Lilly & Co., one of the world's largest pharmaceutical companies, has been in discussions with AtaiBeckley Inc., a clinical-stage biopharmaceutical company focused on developing treatments for mental health conditions including depression and anxiety [1][2]. The acquisition is expected to be worth up to $3.8 billion, according to reports from Bloomberg News [1] and Reuters [3], though the exact valuation remains uncertain as talks are ongoing.
The deal comes after a significant regulatory push by the Trump administration in 2020, which aimed to expedite the approval process for psychedelic drugs like MDMA (also known as ecstasy) and psilocybin (found in mushrooms), which have shown promise in treating conditions such as depression and PTSD [4]. This move has led to increased interest from large pharmaceutical companies in this previously underdeveloped area of research.
AtaiBeckley, based in San Francisco, is a company that has been developing psychedelic-based therapies for mental health issues. Its lead product candidate, ATAI-101, is an MDMA-based treatment for PTSD [5]. The acquisition by Eli Lilly would be significant as it could bring these innovative treatments to a much larger patient base and potentially accelerate their development.
The news of the potential deal has sent AtaiBeckley's stock soaring. On July 16, its shares jumped 50% in pre-market trading after reports surfaced that Eli Lilly was in talks to acquire the company [3]. This acquisition would also be part of a broader trend within the pharmaceutical industry towards expanding into newer and more experimental areas of treatment.